Item 2.02 - Results of Operations and Financial Condition.

The information set forth in the second paragraph of Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 8.01 - Other Events.

On May 3, 2022, Sesen Bio, Inc., (the "Company") announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of the Company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of the Company's proprietary technologies. Pending any decision to undertake any strategic alternative, the Company is continuing its development activities in accordance with its existing business strategy. A copy of the press release issued in connection with the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

As of March 31, 2022, the Company had $169.8 million in cash and cash equivalents, no outstanding debt and less than 0.2 million outstanding warrants. These amounts are preliminary and are subject to change upon completion of the Company's financial statements for the quarterly period ended March 31, 2022.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements regarding the Company's plans to review strategic alternatives with the goal of maximizing shareholder value, which may include the sale of the Company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of the Company's proprietary technologies and the Company's plans to continue its development activities in accordance with its existing business strategy, which are based on the Company's current expectations and inherently involve significant risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that the Company may not be successful in identifying one or more strategic alternatives or ultimately pursuing a strategic alternative that delivers the anticipated benefits or enhances shareholder value, the risk that the Company's exploration and evaluation of strategic alternatives or the public announcement thereof may be disruptive to the Company's business operations or cause the Company's stock price to fluctuate significantly, the risk that the Company's exploration and evaluation of strategic alternatives may be time consuming and involve the dedication of significant resources and may require the Company to incur significant costs and expenses, the risk that the Company's exploration and evaluation of strategic alternatives could divert the attention of the Company's management and its board of directors from the existing business operations, negatively impact the Company's ability to attract, retain and motivate key employees, and expose the Company to potential litigation in connection with the process of exploring strategic alternatives or any resulting transaction, among other risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company's most recent annual report on Form 10-K and the Company's quarterly reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations.

Item 9.01 - Financial Statements and Exhibits.



(d) Exhibits.

Exhibit No.              Description

99.1                       Press Release dated     May 3    , 2022
104                      Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses